

Special Issue

The Gut Microbiome as a Target for the Treatment of Inflammatory Bowel Diseases

Message from the Guest Editors

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic and debilitating disorders characterized by chronic inflammation of the gastrointestinal tract. For a long time, these conditions were primarily viewed as immune-mediated disorders with genetic and environmental factors playing key roles. The exploration of the gut microbiome's role as a target for the treatment of inflammatory bowel diseases (IBDs) is a dynamic and rapidly evolving field that has gained significant attention over the past couple of decades. The topic continues to drive innovative research with the potential to revolutionize our understanding of IBD pathogenesis and treatment approaches. The aim of this Special Issue is to present cutting-edge research and advancements in understanding the pivotal role of the gut microbiome in the treatment of inflammatory bowel diseases (IBDs). By assembling a collection of multidisciplinary research, we aim to provide a comprehensive overview of the potential therapeutic opportunities offered by harnessing the gut microbiome's intricate interactions with the host immune system.

Guest Editors

Dr. Limin Shi

Medicine-Endocrinology and Metabolism Department, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA

Dr. Zhipeng Tao

Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76209, USA

Deadline for manuscript submissions

closed (25 May 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/181684

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).